Dupilumab use in asthma is linked to higher lymphoma risk, especially T and NK cell types, but also shows reduced all-cause ...

Posters presented at ACAAI 2023 Annual Scientific Congress examined dupilumab use in children with moderate-to-severe asthma and in the presence of elevated type 2 biomarkers. Two posters ...

HONOLULU — Children with uncontrolled moderate to severe asthma experienced fewer severe exacerbations requiring systemic corticosteroids when treated with dupilumab, according to a poster ...

SAN FRANCISCO — Children with asthma experienced fewer exacerbations and better control with dupilumab regardless of the duration of their disease, according to a poster at the American Thoracic ...

Dupilumab previously had been shown to be safe and effective in adolescents and adults with moderate-to-severe asthma ... Hybrid Congress 2021: Poster #938. Presented July 10, 2021.

These findings were included in a poster presentation for ... patients with OCS-dependent severe asthma who were treated with either 300 mg dupilumab every 2 weeks or placebo.

Dupilumab improves asthma control in patients with uncontrolled ... 2018; Seattle, WA. Poster P216.

24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma ...

In a separate poster, Mario Castro ... real-world use RAPID registry of asthma patients prescribed dupilumab. Lugogo told MedPage Today that most patients enrolled in the registry to date live ...

A poster presented at the Academy of Managed Care Pharmacy 2021 examined the situation of dupilumab (Dupixent), which is approved for atopic dermatitis (AD), asthma, and chronic rhinosinusitis ...

In patients with persistent, moderate-to-severe asthma and elevated eosinophil levels who used inhaled glucocorticoids and LABAs, dupilumab therapy, as compared with placebo, was associated with ...